Corriente Advisors, LLC Replimune Group, Inc. Transaction History

Corriente Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$28.98 - $39.54 $13 Million - $17.8 Million	-449,879 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$28.5 - $39.37 $17.8 Million - $24.6 Million	-625,121 Reduced 58.15%	449,879 $17.3 Million
Q1 2021 May 18, 2021	SELL	$30.22 - $45.57 $4.84 Million - $7.29 Million	-160,000 Reduced 12.96%	1,075,000 $32.8 Million
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $17 Million - $38 Million	722,500 Added 140.98%	1,235,000 $47.1 Million
Q3 2020 Nov 03, 2020	BUY	$18.85 - $27.0 $518,375 - $742,500	27,500 Added 5.67%	512,500 $11.8 Million
Q2 2020 Aug 14, 2020	BUY	$9.76 - $25.95 $4.73 Million - $12.6 Million	485,000 New	485,000 $12.1 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $545M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Corriente Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Corriente Advisors, LLC with notifications on news.